48 results on '"Shirakawa, Ryutaro"'
Search Results
2. Ral GTPase promotes metastasis of pancreatic ductal adenocarcinoma via elevation of TGF-β1 production
- Author
-
Cao, Mingxin, Li, Xinming, Trinh, Duc-Anh, Yoshimachi, Shingo, Goto, Kota, Sakata, Natsumi, Ishida, Masaharu, Ohtsuka, Hideo, Unno, Michiaki, Wang, Yuxia, Shirakawa, Ryutaro, and Horiuchi, Hisanori
- Published
- 2023
- Full Text
- View/download PDF
3. Down-regulation of RalGTPase-Activating Protein Promotes Colitis-Associated Cancer via NLRP3 Inflammasome Activation
- Author
-
Iida, Tomoya, Hirayama, Daisuke, Minami, Naoki, Matsuura, Minoru, Wagatsuma, Kohei, Kawakami, Kentaro, Nagaishi, Kanna, Nojima, Masanori, Ikeuchi, Hiroki, Hirota, Seiichi, Shirakawa, Ryutaro, Horiuchi, Hisanori, and Nakase, Hiroshi
- Published
- 2020
- Full Text
- View/download PDF
4. Human CTL-based functional analysis shows the reliability of a munc13-4 protein expression assay for FHL3 diagnosis
- Author
-
Shibata, Hirofumi, Yasumi, Takahiro, Shimodera, Saeko, Hiejima, Eitaro, Izawa, Kazushi, Kawai, Tomoki, Shirakawa, Ryutaro, Wada, Taizo, Nishikomori, Ryuta, Horiuchi, Hisanori, Ohara, Osamu, Ishii, Eiichi, and Heike, Toshio
- Published
- 2018
- Full Text
- View/download PDF
5. Inhibitor of Growth 4 (ING4) is a positive regulator of rRNA synthesis
- Author
-
Trinh, Duc-Anh, Shirakawa, Ryutaro, Kimura, Tomohiro, Sakata, Natsumi, Goto, Kota, and Horiuchi, Hisanori
- Published
- 2019
- Full Text
- View/download PDF
6. Endogenous APOBEC3B Overexpression Constitutively Generates DNA Substitutions and Deletions in Myeloma Cells
- Author
-
Yamazaki, Hiroyuki, Shirakawa, Kotaro, Matsumoto, Tadahiko, Hirabayashi, Shigeki, Murakawa, Yasuhiro, Kobayashi, Masayuki, Sarca, Anamaria Daniela, Kazuma, Yasuhiro, Matsui, Hiroyuki, Maruyama, Wataru, Fukuda, Hirofumi, Shirakawa, Ryutaro, Shindo, Keisuke, Ri, Masaki, Iida, Shinsuke, and Takaori-Kondo, Akifumi
- Published
- 2019
- Full Text
- View/download PDF
7. A CD57+ CTL Degranulation Assay Effectively Identifies Familial Hemophagocytic Lymphohistiocytosis Type 3 Patients
- Author
-
Hori, Masayuki, Yasumi, Takahiro, Shimodera, Saeko, Shibata, Hirofumi, Hiejima, Eitaro, Oda, Hirotsugu, Izawa, Kazushi, Kawai, Tomoki, Ishimura, Masataka, Nakano, Naoko, Shirakawa, Ryutaro, Nishikomori, Ryuta, Takada, Hidetoshi, Morita, Satoshi, Horiuchi, Hisanori, Ohara, Osamu, Ishii, Eiichi, and Heike, Toshio
- Published
- 2017
- Full Text
- View/download PDF
8. Prostaglandin E2 inhibits neutrophil extracellular trap formation through production of cyclic AMP
- Author
-
Shishikura, Kyosuke, Horiuchi, Takahiro, Sakata, Natsumi, Trinh, Duc-Anh, Shirakawa, Ryutaro, Kimura, Tomohiro, Asada, Yujiro, and Horiuchi, Hisanori
- Published
- 2016
- Full Text
- View/download PDF
9. Ral GTPases: crucial mediators of exocytosis and tumourigenesis
- Author
-
Shirakawa, Ryutaro and Horiuchi, Hisanori
- Published
- 2015
- Full Text
- View/download PDF
10. Familial hemophagocytic lymphohistiocytosis with the MUNC13-4 mutation: a case report
- Author
-
Mizumoto, Hiroshi, Hata, Daisuke, Yamamoto, Ken, Shirakawa, Ryutaro, Kumakura, Akira, Shiota, Mitsutaka, Yokoyama, Atsushi, Matsubara, Hiroshi, Kobayashi, Michihiro, Nishikomori, Ryuta, Adachi, Soichi, Nakahata, Tatsutoshi, Kita, Toru, Horiuchi, Hisanori, Yasukawa, Masaki, and Ishii, Eiichi
- Published
- 2006
- Full Text
- View/download PDF
11. Genetic subtypes of familial hemophagocytic lymphohistiocytosis: correlations with clinical features and cytotoxic T lymphocyte/natural killer cell functions
- Author
-
Ishii, Eiichi, Ueda, Ikuyo, Shirakawa, Ryutaro, Yamamoto, Ken, Horiuchi, Hisanori, Ohga, Shouichi, Furuno, Kenji, Morimoto, Akira, Imayoshi, Miyoko, Ogata, Yoshiyasu, Zaitsu, Masafumi, Sako, Masahiro, Koike, Kenichi, Sakata, Akifumi, Takada, Hidetoshi, Hara, Toshiro, Imashuku, Shinsaku, Sasazuki, Takehiko, and Yasukawa, Masaki
- Published
- 2005
- Full Text
- View/download PDF
12. Crystal structure of human DAAM1 formin homology 2 domain
- Author
-
Yamashita, Masami, Higashi, Tomohito, Suetsugu, Shiro, Sato, Yusuke, Ikeda, Tomoyuki, Shirakawa, Ryutaro, Kita, Toru, Takenawa, Tadaomi, Horiuchi, Hisanori, Fukai, Shuya, and Nureki, Osamu
- Published
- 2007
13. Elucidation of the molecular mechanism of platelet activation: Dense granule secretion is regulated by small guanosine triphosphate-binding protein Rab27 and its effector Munc13-4
- Author
-
Horiuchi, Hisanori, Shirakawa, Ryutaro, Kondo, Hirokazu, Higashi, Tomohito, Kawato, Mitsunori, and Kita, Toru
- Published
- 2006
14. Ral GTPase–activating protein regulates the malignancy of pancreatic ductal adenocarcinoma.
- Author
-
Yoshimachi, Shingo, Shirakawa, Ryutaro, Cao, Mingxin, Trinh, Duc Anh, Gao, Pan, Sakata, Natsumi, Miyazaki, Kento, Goto, Kota, Miura, Takayuki, Ariake, Kyohei, Maeda, Shimpei, Masuda, Kunihiro, Ishida, Masaharu, Ohtsuka, Hideo, Unno, Michiaki, and Horiuchi, Hisanori
- Abstract
The small GTPases RalA and RalB are members of the Ras family and activated downstream of Ras. Ral proteins are found in GTP‐bound active and GDP‐bound inactive forms. The activation process is executed by guanine nucleotide exchange factors, while inactivation is mediated by GTPase‐activating proteins (GAPs). RalGAPs are complexes that consist of a catalytic α1 or α2 subunit together with a common β subunit. Several reports implicate the importance of Ral in pancreatic ductal adenocarcinoma (PDAC). However, there are few reports on the relationship between levels of RalGAP expression and malignancy in PDAC. We generated RalGAPβ‐deficient PDAC cells by CRISPR‐Cas9 genome editing to investigate how increased Ral activity affects malignant phenotypes of PDAC cells. RalGAPβ‐deficient PDAC cells exhibited several‐fold higher Ral activity relative to control cells. They had a high migratory and invasive capacity. The RalGAPβ‐deficient cells grew more rapidly than control cells when injected subcutaneously into nude mice. When injected into the spleen, the RalGAPβ‐deficient cells formed larger splenic tumors with more liver metastases, and unlike controls, they disseminated into the abdominal cavity. These results indicate that RalGAPβ deficiency in PDAC cells contributes to high activities of RalA and RalB, leading to enhanced cell migration and invasion in vitro, and tumor growth and metastasis in vivo. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
15. Double prenylation of SNARE protein Ykt6 is required for lysosomal hydrolase trafficking.
- Author
-
Sakata, Natsumi, Shirakawa, Ryutaro, Goto, Kota, Trinh, Duc Anh, and Horiuchi, Hisanori
- Subjects
- *
SNARE proteins , *ISOPRENYLATION , *GOLGI apparatus , *CATHEPSIN D , *EXTRACELLULAR space - Abstract
Ykt6 is an evolutionarily conserved SNARE protein regulating Golgi membrane fusion and other diverse membrane trafficking pathways. Unlike most SNARE proteins, Ykt6 lacks a transmembrane domain but instead has a tandem cysteine motif at the C-terminus. Recently, we have demonstrated that Ykt6 undergoes double prenylation at the C-terminal two cysteines first by farnesyltransferase and then by a newly identified protein prenyltransferase named geranylgeranyltransferase type-III (GGTase-III). GGTase-III consists of a novel α subunit prenyltransferase alpha subunit repeat containing 1 (PTAR1) and the β subunit of Rab geranylgeranyltransferase. PTAR1 knockout (KO) cells, where Ykt6 is singly prenylated with a farnesyl moiety, exhibit structural and functional abnormalities in the Golgi apparatus with delayed intra-Golgi trafficking and impaired protein glycosylation. It remains unclear whether the second prenylation of Ykt6 is required for proper trafficking of lysosomal hydrolases from Golgi to lysosomes. Here, we show that lysosomal hydrolases, cathepsin D and β-hexosaminidase, were missorted at the trans -Golgi network and secreted into the extracellular space in PTAR1 KO cells. Moreover, maturation of these hydrolases was disturbed. LC3B, an autophagy marker, was accumulated in PTAR1 KO cells, suggesting defects in cellular degradation pathways. Thus, doubly prenylated Ykt6, but not singly prenylated Ykt6, is critical for the efficient sorting and trafficking of acid hydrolases to lysosomes. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
16. A SNARE geranylgeranyltransferase essential for the organization of the Golgi apparatus.
- Author
-
Shirakawa, Ryutaro, Goto‐Ito, Sakurako, Goto, Kota, Wakayama, Shonosuke, Kubo, Haremaru, Sakata, Natsumi, Trinh, Duc Anh, Yamagata, Atsushi, Sato, Yusuke, Masumoto, Hiroshi, Cheng, Jinglei, Fujimoto, Toyoshi, Fukai, Shuya, and Horiuchi, Hisanori
- Subjects
- *
GOLGI apparatus , *SNARE proteins , *DIMETHYLALLYLTRANSTRANSFERASE , *ISOPRENYLATION , *EUKARYOTIC cells , *CELLULAR signal transduction - Abstract
Protein prenylation is essential for many cellular processes including signal transduction, cytoskeletal reorganization, and membrane trafficking. Here, we identify a novel type of protein prenyltransferase, which we named geranylgeranyltransferase type‐III (GGTase‐III). GGTase‐III consists of prenyltransferase alpha subunit repeat containing 1 (PTAR1) and the β subunit of RabGGTase. Using a biotinylated geranylgeranyl analogue, we identified the Golgi SNARE protein Ykt6 as a substrate of GGTase‐III. GGTase‐III transfers a geranylgeranyl group to mono‐farnesylated Ykt6, generating doubly prenylated Ykt6. The crystal structure of GGTase‐III in complex with Ykt6 provides structural basis for Ykt6 double prenylation. In GGTase‐III‐deficient cells, Ykt6 remained in a singly prenylated form, and the Golgi SNARE complex assembly was severely impaired. Consequently, the Golgi apparatus was structurally disorganized, and intra‐Golgi protein trafficking was delayed. Our findings reveal a fourth type of protein prenyltransferase that generates geranylgeranyl‐farnesyl Ykt6. Double prenylation of Ykt6 is essential for the structural and functional organization of the Golgi apparatus. Synopsis: Three types of protein prenyltransferases are known to catalyse protein farnesylation and geranylgeranylation in eukaryotic cells. Here, a fourth class formed by PTAR1 heterodimerization with RabGGTβ is found to drive double prenylation of Golgi SNARE Ykt6, which is critical for Golgi complex maintenance and function in mammalian cells. Human PTAR1 and RabGGTβ form a fourth type of protein prenyltransferase, named GGTase‐III.GGTase‐III transfers a geranylgeranyl group to mono‐farnesylated Ykt6, generating doubly‐prenylated Ykt6.Structural analyses reveal the catalytic mechanism of Ykt6 double prenylation.Doubly‐prenylated Ykt6 is required for maintaining structure and function of the Golgi apparatus. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
17. APOBEC3B reporter myeloma cell lines identify DNA damage response pathways leading to APOBEC3B expression.
- Author
-
Yamazaki, Hiroyuki, Shirakawa, Kotaro, Matsumoto, Tadahiko, Kazuma, Yasuhiro, Matsui, Hiroyuki, Horisawa, Yoshihito, Stanford, Emani, Sarca, Anamaria Daniela, Shirakawa, Ryutaro, Shindo, Keisuke, and Takaori-Kondo, Akifumi
- Subjects
DNA damage ,CELL lines ,DEOXYRIBOZYMES ,APOLIPOPROTEIN B ,MULTIPLE myeloma ,POLYPEPTIDES - Abstract
Apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like (APOBEC) DNA cytosine deaminase 3B (A3B) is a DNA editing enzyme which induces genomic DNA mutations in multiple myeloma and in various other cancers. APOBEC family proteins are highly homologous so it is especially difficult to investigate the biology of specifically A3B in cancer cells. To easily and comprehensively investigate A3B function in myeloma cells, we used CRISPR/Cas9 to generate A3B reporter cells that contain 3×FLAG tag and IRES-EGFP sequences integrated at the end of the A3B gene. These reporter cells stably express 3xFLAG tagged A3B and the reporter EGFP and this expression is enhanced by known stimuli, such as PMA. Conversely, shRNA knockdown of A3B decreased EGFP fluorescence and 3xFLAG tagged A3B protein levels. We screened a series of anticancer treatments using these cell lines and identified that most conventional therapies, such as antimetabolites or radiation, exacerbated endogenous A3B expression, but recent molecular targeted therapeutics, including bortezomib, lenalidomide and elotuzumab, did not. Furthermore, chemical inhibition of ATM, ATR and DNA-PK suppressed EGFP expression upon treatment with antimetabolites. These results suggest that DNA damage triggers A3B expression through ATM, ATR and DNA-PK signaling. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
18. Downregulation of RalGTPase-activating protein promotes invasion of prostatic epithelial cells and progression from intraepithelial neoplasia to cancer during prostate carcinogenesis.
- Author
-
Uegaki, Masayuki, Kita, Yuki, Shirakawa, Ryutaro, Teramoto, Yuki, Kamiyama, Yuki, Saito, Ryoichi, Yoshikawa, Takeshi, Sakamoto, Hiromasa, Goto, Takayuki, Akamatsu, Shusuke, Yamasaki, Toshinari, Inoue, Takahiro, Suzuki, Akira, Horiuchi, Hisanori, Ogawa, Osamu, and Kobayashi, Takashi
- Subjects
PROSTATE cancer ,EPITHELIAL cells ,GTPASE-activating protein ,CARCINOGENESIS ,DOWNREGULATION - Abstract
RalGTPase-activating protein (RalGAP) is an important negative regulator of small GTPases RalA/B that mediates various oncogenic signaling pathways in various cancers. Although the Ral pathway has been implicated in prostate cancer (PCa) development and progression, the significance of RalGAP in PCa has been largely unknown. We examined RalGAPα2 expression using immunohistochemistry on two independent tissue microarray sets. Both datasets demonstrated that the expression of RalGAPα2 was significantly downregulated in PCa tissues compared to adjacent benign prostatic epithelia. Silencing of RalGAPα2 by short hairpin RNA enhanced migration and invasion abilities of benign and malignant prostate epithelial cell lines without affecting cell proliferation. Exogenous expression of wild-type RalGAP, but not the GTPase-activating protein activity-deficient mutant of RalGAP, suppressed migration and invasion of multiple PCa cell lines and was phenocopied by pharmacological inhibition of RalA/B. Loss of Ralgapa2 promoted local microscopic invasion of prostatic intraepithelial neoplasia without affecting tumor growth in a Pten -deficient mouse model for prostate tumorigenesis. Our findings demonstrate the functional significance of RalGAP downregulation to promote invasion ability, which is a property necessary for prostate carcinogenesis. Thus, loss of RalGAP function has a distinct role in promoting progression from prostatic intraepithelial neoplasia to invasive adenocarcinoma. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
19. Su1808 – Downregulation of Ralgtpase-Activating Protein Leads to Exacerbation of Murine Dextran Sulfate Sodium-Induced Colitis
- Author
-
Iida, Tomoya, Minami, Naoki, Matsuura, Minoru, Shirakawa, Ryutaro, Horiuchi, Hisanori, and Nakase, Hiroshi
- Published
- 2019
- Full Text
- View/download PDF
20. Munc13 - 4 ワ GTPガタ Rab27 ケツゴウ タンパクシツ デ アリ ケッショウバン ノウセン カリュウ ブンピ オ セイギョスル
- Author
-
Shirakawa, Ryutaro, 前川, 平, 野間, 昭典, and 長澤, 丘司
- Published
- 2007
21. The antimalarial drugs chloroquine and primaquine inhibit pyridoxal kinase, an essential enzyme for vitamin B6 production.
- Author
-
Kimura, Tomohiro, Shirakawa, Ryutaro, Yaoita, Nobuhiro, Hayashi, Takashi, Nagano, Keisuke, and Horiuchi, Hisanori
- Subjects
- *
TRYPANOSOMIASIS treatment , *CHLOROQUINE , *PRIMAQUINE , *VITAMIN B6 , *QUINOLINE derivatives , *ANTIMALARIALS , *CARRIER proteins , *THERAPEUTICS - Abstract
Quinoline derivatives such as chloroquine and primaquine are widely used for the treatment of malaria. These drugs are also used for the treatment of trypanosomiasis, and more recently for cancer therapy. However, molecular target(s) of these drugs remain unclear. In this study, we have identified human pyridoxal kinase as a binding protein of primaquine. Primaquine inhibited pyridoxal kinases of malaria, trypanosome and human, while chloroquine inhibited only malaria pyridoxal kinase. Thus, we have identified pyridoxal kinase as a possible target molecule of the antimalarial drugs chloroquine and primaquine. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
22. Platelet αIIbβ3 integrin binds to SARS-CoV-2 spike protein of alpha strain but not wild type and omicron strains.
- Author
-
Ito, Koyu, Goto, Kota, Shirakawa, Ryutaro, Horiuchi, Hisanori, and Ogasawara, Kouetsu
- Subjects
- *
BLOOD platelet aggregation , *SARS-CoV-2 Omicron variant , *COVID-19 , *SARS-CoV-2 , *BLOOD platelets , *CARRIER proteins - Abstract
Severe acute respiratory syndrome coronavirus (SARS-CoV)-2 causes a pandemic infectious disease, Coronavirus disease 2019 (COVID-19). It causes respiratory infection. Then, it progresses into a systemic infection by involving other organs. This progression mechanism remains to be elucidated, although thrombus formation plays an important role in its progression. Platelets is involved in the thrombus formation by aggregating each other through association of activated αIIbβ3 integrin with the Arg-Gly-Asp (RGD) motif-containing its ligands such as fibrinogen and von Willebrand factor. SARS-CoV-2 enters host cells through association of the spike protein (S-protein) with its receptor, angiotensin-converting enzyme 2 (ACE-2), on the host cells. While presence of ACE2 in platelets is suspicious, S-protein harbors the RGD sequences within its receptor binding domain. Therefore, it could be possible SARS-CoV-2 enter platelets through association of S-protein with αIIbβ3. In this study, we found that receptor binding domain of S-protein of WT SARS-CoV-2 strain barely bound to isolated healthy human platelets. In contrast, highly toxic alpha-strain-based N501Y substitution strongly bound to platelets in a RGD dependent manner, although binding of S protein did not induce platelet aggregation or activation. This binding may serve for transferring the infection to systemic organs. • N501Y mutation on SARS-CoV-2 spike protein enhanced binding to platelet through αIIbβ3 integrin-dependent manner. • The binding did not induce neither platelet aggregation nor platelet activation. • Integrin αIIbβ3 on platelet may serve for transferring viral infection to systemic organs. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
23. A complete Rab screening reveals novel insights in Weibel-Palade body exocytosis.
- Author
-
Zografou, Sofia, Basagiannis, Dimitris, Papafotika, Alexandra, Shirakawa, Ryutaro, Horiuchi, Hisanori, Auerbach, Daniel, Fukuda, Mitsunori, and Christoforidis, Savvas
- Subjects
EXOCYTOSIS ,CELL membranes ,MOLECULES ,BLOOD-vessel abnormalities ,INFLAMMATION - Abstract
Weibel-Palade bodies (WPBs) are endothelial-cell-specific organelles that, upon fusion with the plasma membrane, release cargo molecules that are essential in blood vessel abnormalities, such as thrombosis and inflammation, as well as in angiogenesis. Despite the importance of WPBs, the basic mechanisms that mediate their secretion are only poorly understood. Rab GTPases play fundamental role in the trafficking of intracellular organelles. Yet, the only known WPB-associated Rabs are Rab27a and Rab3d. To determine the full spectrum of WPB-associated Rabs we performed a complete Rab screening by analysing the localisation of all Rabs in WPBs and their involvement in the secretory process in endothelial cells. Apart from Rab3 and Rab27, we identified three additional Rabs, Rab15 (a previously reported endocytic Rab), Rab33 and Rab37, on the WPB limiting membrane. A knockdown approach using siRNAs showed that among these five WPB Rabs only Rab3, Rab27 and Rab15 are required for exocytosis. Intriguingly, we found that Rab15 cooperates with Rab27a in WPB secretion. Furthermore, a specific effector of Rab27, Munc13-4, appears to be also an effector of Rab15 and is required for WPB exocytosis. These data indicate that WPB secretion requires the coordinated function of a specific group of Rabs and that, among them, Rab27a and Rab15, as well as their effector Munc13-4, cooperate to drive exocytosis. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
24. Tuberous Sclerosis Tumor Suppressor Complex-like Complexes Act as GTPase-activating Proteins for Ral GTPases.
- Author
-
Shirakawa, Ryutaro, Fukai, Shuya, Kawato, Mitsunori, Higashi, Tomohito, Kondo, Hirokazu, Ikeda, Tomoyuki, Nakayama, Ei, Okawa, Katsuya, Nureki, Osamu, Kimura, Takeshi, Kita, Toru, and Horiuchi, Hisanori
- Subjects
- *
TUBEROUS sclerosis , *TUMOR suppressor proteins , *GTPASE-activating protein , *G proteins , *EPIDERMAL growth factor - Abstract
The small GTPases RalA and RalB are multifunctional proteins regulating a variety of cellular processes. Like other GTPases, the activity of Ral is regulated by the opposing effects of guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs). Although several RaIGEFs have been identified and characterized, the molecular identity of RalGAP remains unknown. Here, we report the first molecular identification of RalGAPs, which we have named RalGAP1 and RalGAP2. They are large heterodimeric complexes, each consisting of a catalytic α1 or α2 subunit and a common β subunit. These RaIGAP complexes share structural and catalytic similarities with the tuberous sclerosis tumor suppressor complex, which acts as a GAP for Rheb. In vitro GTPase assays revealed that recombinant RalGAP1 accelerates the GTP hydrolysis rate of RalA by 280,000-fold. Heterodimerization was required for this GAP activity. In PC12 cells, knockdown of the β subunit led to sustained Ral activation upon epidermal growth factor stimulation, indicating that the RalGAPs identified here are critical for efficient termination of Ral activation induced by extracellular stimuli. Our identification of RalGAPs will enable further understanding of Ral signaling in many biological and pathological processes. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
25. Regulation of Platelet Dense Granule Secretion by the Ral GTPase-Exocyst Pathway.
- Author
-
Kawato, Mitsunori, Shirakawa, Ryutaro, Kondo, Hirokazu, Higashi, Tomohito, Ikeda, Tomoyuki, Okawa, Katsuya, Fukai, Shuya, Nureki, Osamu, Kita, Toru, and Horiuchi, Hisanori
- Subjects
- *
CYTOPLASMIC granules , *CELL membranes , *BLOOD platelets , *BIOLOGICAL transport , *CYCLIC guanylic acid , *GUANOSINE triphosphatase - Abstract
Non-hydrolyzable GTP analogues, such as guanosine 5'-(β,γ-imido)triphosphate (GppNHp), induce granule secretion from permeabilized platelets in the absence of increased intracellular Ca2+. Here, we show that the GppNHp-induced dense granule secretion from permeabilized platelets occurred concomitantly with the activation of small GTPase Ral. This secretion was inhibited by the addition of GTP-Ral-binding domain (RBD) of Sec5, which is a component of the exocyst complex known to function as a tethering factor at the plasma membrane for vesides. We generated an antibody against Sec5-RBD, which abolished the interaction between GTP-Ral and the exocyst complex in vitro. The addition of this antibody inhibited the GppNHp-induced secretion. These data indicate that Rat mediates the GppNHp-induced dense granule secretion from permeabilized platelets through interaction with its effector, the exocyst complex. Furthermore, GppNHp enhanced the Ca2+ sensitivity of dense granule secretion from permeabilized platelets, and this enhancement was inhibited by Sec5-RBD. In intact platelets, the association between Rat and the exodyst complex was induced by thrombin stimulation with a time course similar to that of dense granule secretion and Ral activation. Taken together, our results suggest that the Ral-exocyst pathway participates in the regulation of platelet dense granule secretion by enhancing the Ca2+ sensitivity of the secretion. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
26. Asymmetric Coiled-Coil Structure with Guanine Nucleotide Exchange Activity
- Author
-
Sato, Yusuke, Shirakawa, Ryutaro, Horiuchi, Hisanori, Dohmae, Naoshi, Fukai, Shuya, and Nureki, Osamu
- Subjects
- *
EXOCYTOSIS , *GUANOSINE triphosphatase , *YEAST , *NUCLEOTIDES - Abstract
Summary: Vesicular traffic during exocytosis is regulated by Rab GTPase, Sec4p in yeast, which is activated by a guanine nucleotide exchange factor (GEF) called Sec2p. The GEF activity is localized in the N-terminal 160 residues of Sec2p, which lacks sequence similarity with any other GEFs with known structures, and thereby the guanine nucleotide exchange mechanism by Sec2p remains unknown. Here, we report the crystal structure of the Sec2p GEF domain at 3.0 Å resolution. The structure unexpectedly consists of a homodimeric, parallel coiled coil that extends over 180 Å. Pull-down and guanine nucleotide exchange analyses on a series of deletion and point mutants of Sec2p unveiled the catalytic residues for its GEF activity as well as the Sec4p binding site, thus presenting a nucleotide exchange mechanism by a simple coiled coil. The present functional analyses allow us to build the Sec2p:Sec4p complex model, which explains the specificity for Rab GTPases by their respective GEF proteins. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
27. Constitutive GDP/GTP Exchange and Secretion-dependent GTP Hydrolysis Activity for Rab27 in Platelets.
- Author
-
Kondo, Hirokazu, Shirakawa, Ryutaro, Higashi, Tomohito, Kawato, Mitsunori, Fukuda, Mitsunori, Kita, Toru, and Horiuchi, Hisanori
- Subjects
- *
BLOOD platelets , *GUANOSINE triphosphate , *THIN layer chromatography , *HYDROLYSIS , *NUCLEOTIDES - Abstract
We have previously demonstrated that Rab27 regulates dense granule secretion in platelets. Here, we analyzed the activation status of Rab27 using the thin layer chromatography method analyzing nucleotides bound to immunoprecipitated Rab27 and the pull-down method quantifying Rab27 bound to the GTP-Rab27-binding domain (synaptotagmin-like protein (Slp)-homology domain) of its specific effector, Slac2-b. We found that Rab27 was predominantly present in the GTP-bound form in unstimulated platelets due to constitutive GDP/GTP exchange activity. The GTP-bound Rab27 level drastically decreased due to enhanced GTP hydrolysis activity upon granule secretion. In permeabilized platelets, increase of Ca2+ concentration induced dense granule secretion with concomitant decrease of GTP-Rab27, whereas in non-hydrolyzable GTP analogue GppNHp (β-γ-imidoguanosine 5′-triphosphate)-loaded permeabilized platelets, the GTP (GppNHp)-Rab27 level did not decrease upon the Ca2+-induced secretion, These data suggested that GTP hydrolysis of Rab27 was not necessary for inducing the secretion. Taken together, Rab27 is maintained in the active status in unstimulated platelets, which could function to keep dense granules in a preparative status for secretion. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
28. Munc13-4 Is a GTP-Rab27-binding Protein Regulating Dense Core Granule Secretion in Platelets.
- Author
-
Shirakawa, Ryutaro, Higashi, Tomohito, Tabuchi, Arata, Yoshioka, Akira, Nishioka, Hiroaki, Fukuda, Mitsunori, Kita, Toru, and Horiuchi, Hisanori
- Subjects
- *
BLOOD platelets , *ADENOSINE diphosphate , *SEROTONIN , *BIOCHEMISTRY , *BIOLOGY , *CHEMISTRY - Abstract
Platelets store self. agonists such as ADP and serotonin in dense core granules. Although exocytosis of these granules is crucial for hemostasis and thrombosis, the underlying mechanism is not fully understood. Here, we show that incubation of permeabilized platelets with unprenylated active mutant Rab27A-Q78L, wild type Rab27A, and Rab27B inhibited the secretion, whereas inactive mutant Rab27A-T23N and other GTPases had no effects. Furthermore, we affinity-purified a GTPRab27A-binding protein in platelets and identified it as Munc13-4, a homologue of Munc13-1 known as a priming factor for neurotransmitter release. Recombinant Munc13-4 directly bound to GTP-Rab27A and -Rab27B in vitro, but not other GTPases, and enhanced secretion in an in vitro assay. The inhibition of secretion by unprenylated Rab27A was rescued by the addition of Munc13-4, suggesting that Munc13-4 mediates the function of GTP-Rab27. Thus, Rab27 regulates the dense core granule secretion in platelets by employing its binding protein, Munc13-4. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
29. Molecular Dissection of α- and Dense-Core Granule Secretion of Platelets.
- Author
-
YOSHIOKA, AKIRA, HORIUCHI, HISANORI, SHIRAKAWA, RYUTARO, NISHIOKA, HIROAKI, TABUCHI, ARATA, HIGASHI, TOMOHITO, YAMAMOTO, AKITSUGU, and KITA, TORU
- Published
- 2001
- Full Text
- View/download PDF
30. RAB27 REGULATES THE CA2+-INDUCED DENSE-GRANULE SECRETION IN PLATELETS
- Author
-
Kondo, Hirokazu, Horiuchi, Hisanori, Shirakawa, Ryutaro, Higashi, Tomohito, Tabuchi, Arata, Fukuda, Mitsunori, and Kita, Toru
- Published
- 2004
- Full Text
- View/download PDF
31. Rapid diagnosis of FHL3 by flow cytometric detection of intraplatelet Munc13-4 protein.
- Author
-
Murata, Yuuki, Yasumi, Takahiro, Shirakawa, Ryutaro, Izawa, Kazushi, Sakai, Hidemasa, Abe, Junya, Tanaka, Naoko, Kawai, Tomoki, Oshima, Koichi, Saito, Megumu, Nishikomori, Ryuta, Ohara, Osamu, Ishii, Eiichi, Nakahata, Tatsutoshi, Horiuchi, Hisanori, and Heike, Toshio
- Subjects
- *
FLOW cytometry , *HEMATOLOGY , *GENETIC disorders , *HEMATOPOIETIC stem cell transplantation , *EXOCYTOSIS - Abstract
Familial hemophagocytic lymphohistiocytosis (FHL) is a potentially lethal genetic disorder of immune dysregulation that requires prompt and accurate diagnosis to initiate life-saving immunosuppressive therapy and to prepare for hematopoietic stem cell transplantation. In the present study, 85 patients with hemophagocytic lymphohistiocytosis were screened for FHL3 by Western blotting using platelets and by natural killer cell lysosomal exocytosis assay. Six of these patients were diagnosed with FHL3. In the acute disease phase requiring platelet transfusion, it was difficult to diagnose FHL3 by Western blot analysis or by lysosomal exocytosis assay. In contrast, the newly established flow cytometric analysis of intraplatelet Munc13-4 protein expression revealed bimodal populations of normal and Munc13-4-deficient platelets. These findings indicate that flow cytometric detection of intraplatelet Munc13-4 protein is a sensitive and reliable method to rapidly screen for FHL3 with a very small amount of whole blood, even in the acute phase of the disease. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
32. Biochemical Characterization of the Rho GTPase-regulated Actin Assembly by Diaphanous-related Formins, mDia1 and Daam1, in Platelets.
- Author
-
Higashi, Tomohito, Ikeda, Tomoyuki, Shirakawa, Ryutaro, Kondo, Hirokazu, Kawato, Mitsunori, Horiguchi, Masahito, Okuda, Tomohiko, Okawa, Katsuya, Fukai, Shuya, Nureki, Osamu, Kita, Toru, and Horiuchi, Hisanori
- Subjects
- *
RHO GTPases , *ACTIN , *BLOOD platelets , *GUANOSINE triphosphatase , *NUCLEATION - Abstract
The diaphanous-related formins are actin nucleating and elongating factors. They are kept in an inactive state by an intramolecular interaction between the diaphanous inhibitory domain (DID) and the diaphanous-autoregulatory domain (DAD). It is considered that the dissociation of this autoinhibitory interaction upon binding of GTP-bound Rho to the GTPase binding domain next to DID induces exposure of the FH1-FH2 domains, which assemble actin filaments. Here, we isolated two diaphanous-related formins, mDia1 and Daam1, in platelet extracts by GTP-RhoA affinity column chromatography. We characterized them by a novel assay, where beads coated with the FH1-FH2-DAD domains of either mDia1 or Daam1 were incubated with platelet cytosol, and the assembled actin filaments were observed after staining with rhodamine-phalloidin. Both formins generated fluorescent filamentous structures on the beads. Quantification of the fluorescence intensity of the beads revealed that the initial velocity in the presence of mDia1 was more than 10 times faster than in the presence of Daam1, The actin assembly activities of both FH1-FH2-DADs were inhibited by adding cognate DID domains. GTP-RhoA, -RhoB, and -RhoC, but not GTP-Rac1 or -Cdc42, bound to both mDia1 and Daam1 and efficiently neutralized the inhibition by the DID domains, The association between RhoA and Daam1 was induced by thrombin stimulation in platelets, and RhoA-bound endogenous formins induced actin assembly, which was inhibited by the DID domains of Daam1 and mDia1. Thus, mDia1 and Daam1 are platelet actin assembly factors having distinct efficiencies, and they are directly regulated by Rho GTPases. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
33. Direct demonstration of involvement of the adaptor protein ShcA in the regulation of Ca2+-induced platelet aggregation
- Author
-
Higashi, Tomohito, Yoshioka, Akira, Shirakawa, Ryutaro, Tabuchi, Arata, Nishioka, Hiroaki, Kita, Toru, and Horiuchi, Hisanori
- Subjects
- *
STREPTOLYSIN , *TYROSINE , *CYTOSOL , *BLOOD platelets - Abstract
Platelet aggregation is mediated by conformational change of integrin αIIbβ3. Tyrosine-phosphorylation of cytoplasmic domain of β3 upon platelet activation has been demonstrated to play a critical role in this process. Recently, the adaptor protein ShcA has been shown to bind to the tyrosine-phosphorylated β3, while it remains open whether ShcA plays any role in platelet aggregation. Here, we show that ShcA bound to tyrosine-phosphorylated β3-tail peptide through its phosphotyrosine-binding domain in vitro. Then, we examined the involvement of ShcA in platelet aggregation by a previously established in vitro assay using platelets permeabilized with streptolysin-O, where exogenous addition of platelet cytosol is required for reconstitution of the Ca2+-induced aggregation. When ShcA was specifically depleted with anti-ShcA antibody from the cytosol, this ShcA-depleted cytosol lost the aggregation-supporting activity, which was rescued by addition of purified recombinant ShcA. Thus, ShcA is essential for the Ca2+-induced platelet aggregation. [Copyright &y& Elsevier]
- Published
- 2004
- Full Text
- View/download PDF
34. GARNL1, a major RalGAP α subunit in skeletal muscle, regulates insulin-stimulated RalA activation and GLUT4 trafficking via interaction with 14-3-3 proteins.
- Author
-
Chen, Qiaoli, Quan, Chao, Xie, Bingxian, Chen, Liang, Zhou, Shuilian, Toth, Rachel, Campbell, David G., Lu, Shuangshuang, Shirakawa, Ryutaro, Horiuchi, Hisanori, Li, Chaojun, Yang, Zhongzhou, MacKintosh, Carol, Wang, Hong Yu, and Chen, Shuai
- Subjects
- *
SKELETAL muscle , *INSULIN regulation , *GLUTAMINE , *MUSCLE contraction , *GLUCOSE transporters , *CELL membranes - Abstract
Abstract: Insulin and muscle contraction each stimulate translocation of the glucose transporter GLUT4 to the plasma membrane in skeletal muscle, an important process regulating whole-body glucose homeostasis. RalA mediates insulin-stimulated GLUT4 translocation; however, it is unclear how this small GTPase is regulated in skeletal muscle in response to insulin. Here, we identified GARNL1/RalGAPα1, a major α subunit of the Ral-GTPase activating protein in skeletal muscle, as a protein whose phosphorylation and binding to the regulatory 14-3-3 proteins is stimulated by insulin and also by muscle contraction. The insulin-stimulated interaction with 14-3-3 involved PKB/Akt-mediated phosphorylation of Thr735 on GARNL1/RalGAPα1. Knockdown of GARNL1/RalGAPα1 increased, while overexpression of GARNL1/RalGAPα1Thr735Ala mutant protein decreased, the RalA activation and the RalA-dependent GLUT4 translocation in response to insulin in muscle cells. These findings show that GARNL1/RalGAPα1 is the missing link that connects the insulin-PKB/Akt signaling pathway with the activation of the RalA small GTPase in muscle cells. GARNL1/RalGAPα1 and its phosphorylation and/or binding to 14-3-3s are critical for GLUT4 trafficking through RalA in muscle cells. [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
35. Munc 13-4 reconstitutes calcium-dependent SNARE-mediated membrane fusion.
- Author
-
Boswell, Kristin L., James, Declan J., Esquibel, Joseph M., Bruinsma, Stephen, Shirakawa, Ryutaro, Horiuchi, Hisanori, and Martin, Thomas F. J.
- Subjects
- *
PROTEIN analysis , *EXOCYTOSIS , *LIPOSOMES , *PROTEIN binding , *CALCIUM ions - Abstract
Munc13-4 is a widely expressed member of the CAPS/Munc13 protein family proposed to function in priming secretory granules for exocytosis. Munc13-4 contains N- and C-terminal C2 domains (C2A and C2B) predicted to bind Ca2+ but Ca2+-dependent regulation of Munc13-4 activity has not been described. The C2 domains bracket a predicted SNARE-binding domain, but whether Munc13-4 interacts with SNARE proteins is unknown. We report that Munc13-4 bound Ca2+ and restored Ca2+-dependent granule exocytosis to permeable cells (platelets, mast, and neuroendocrine cells) dependent on putative Ca2+-binding residues in C2A and C2B. Munc13-4 exhibited Ca2+-stimulated SNARE interactions dependent on C2A and Ca2+-dependent membrane binding dependent on C2B. In an apparent coupling of membrane and SNARE binding, Munc13-4 stimulated SNARE-dependent liposome fusion dependent on putative Ca2+-binding residues in both C2A and C2B domains. Munc13-4 is the first priming factor shown to promote Ca2+-dependent SNARE complex formation and SNARE-mediated liposome fusion. These properties of Munc13-4 suggest its function as a Ca2+ sensor at rate-limiting priming steps in granule exocytosis. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
36. Flightless-I (Fli-I) Regulates the Actin Assembly Activity of Diaphanous-related Formins (DRFs) Daam1 and mDia1 in Cooperation with Active Rho GTPase.
- Author
-
Higashi, Tomohito, Ikeda, Tomoyuki, Murakami, Takaaki, Shirakawa, Ryutaro, Kawato, Mitsunori, Okawa, Katsuya, Furuse, Mikio, Kimura, Takeshi, Kita, Toru, and Horiuchi, Hisanori
- Subjects
- *
EUKARYOTIC cells , *ACTIN , *CYTOSKELETON , *RHO GTPases , *CELLS - Abstract
Eukaryotic cells dynamically reorganize the actin cytoskeleton to regulate various cellular activities, such as cell shape change, cell motility, cytokinesis, and vesicular transport. Diaphanous-related formins (DRFs), such as Daam1 and mDia1, play central roles in actin dynamics through assembling linear actin filaments. It has been reported that the GTP-bound active Rho binds directly to DRFs and partially unleashes the intramolecular autoinhibition of DRFs. However, whether proteins other than Rho involve the regulation of the actin assembly activity of DRFs has been unclear. Here, we show that Flightless-I (Fli-I), a gelsolin family protein essential for early development, binds directly to Daam1 and mDia1. Fli-I enhances the intrinsic actin assembly activity of Daam1 and mDia1 in vitro and is required for Daam1-induced actin assembly in living cells. Furthermore, Fli-I promotes the GTP-bound active Rho-mediated relief of the autoinhibition of Daam1 and mDia1. Thus, Fli-I is a novel positive regulator of Rho-induced linear actin assembly mediated by DRFs. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
37. Direct Demonstration of Involvement of Protein Kinase Cα in the Ca[sup 2+]-induced Platelet Aggregation.
- Author
-
Tabuchi, Arata, Yoshioka, Akira, Higashi, Tomohito, Shirakawa, Ryutaro, Nishioka, Hiroaki, Kita, Toru, and Horiuchi, Hisanori
- Subjects
- *
PROTEIN kinase C , *BLOOD platelet aggregation - Abstract
Platelets play critical roles in hemostasis and thrombosis through their aggregation following activation of integrin α[sub IIb]β[sub 3]. However, the molecular mechanism of the integrin activation inside platelets remains largely unknown. Pharmacological experiments have demonstrated that protein kinase C (PKC) plays an important role in platelet aggregation. Because PKC inhibitors can have multiple substrates and given that non-PKC-phorbol ester-binding signaling molecules have been demonstrated to play important roles, the precise involvement of PKC in cellular functions requires re-evaluation. Here, we have established an assay for analyzing the Ca[sup 2+]-induced aggregation of permeabilized platelets. The aggregation of platelets was inhibited by the addition of the arginine-glycine-aspartate-serine peptide, an integrin-binding peptide inhibitor of α[sub IIb]β[sub 3], suggesting that the aggregation was mediated by the integrin. The aggregation was also dependent on exogenous ATP and platelet cytosol, indicating the existence of essential cytosolic factors required for the aggregation. To examine the role of PKC in the aggregation assay, we immunodepleted PKCα and β from the cytosol. The PKC-depleted cytosol lost the aggregation-supporting activity, which was recovered by the addition of purified PKCα. Furthermore, the addition of purified PKCα in the absence of cytosol did not support the aggregation, whereas the cytosol containing less PKC supported it efficiently, suggesting that additional factors besides PKC would also be required. Thus, we directly demonstrated that PKCα is involved in the regulation of Ca[sup 2+]-induced platelet aggregation. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
38. von Willebrand factor Ristocetin co-factor activity to von Willebrand factor antigen level ratio for diagnosis of acquired von Willebrand syndrome caused by aortic stenosis.
- Author
-
Okubo N, Sugawara S, Fujiwara T, Sakatsume K, Doman T, Yamashita M, Goto K, Tateishi M, Suzuki M, Shirakawa R, Eura Y, Kokame K, Hayakawa M, Matsumoto M, Kawate Y, Miura M, Takiguchi H, Soga Y, Shirai S, Ando K, Arai Y, Nakayoshi T, Fukumoto Y, Takahama H, Yasuda S, Tamura T, Watanabe S, Kimura T, Yaoita N, Shimokawa H, Saiki Y, Kaikita K, Tsujita K, Yoshii S, Nakase H, Fujimaki SI, and Horiuchi H
- Abstract
Background: Severe aortic stenosis (AS) causes acquired von Willebrand syndrome by the excessive shear stress-dependent cleavage of high molecular weight multimers of von Willebrand factor (VWF). While the current standard diagnostic method is so-called VWF multimer analysis that is western blotting under nonreducing conditions, it remains unclear whether a ratio of VWF Ristocetin co-factor activity (VWF:RCo) to VWF antigen levels (VWF:Ag) of <0.7, which can be measured with an automated coagulation analyzer in clinical laboratories and is used for the diagnosis of hereditary von Willebrand disease., Objectives: To evaluated whether the VWF:RCo/VWF:Ag is useful for the diagnosis of AS-induced acquired von Willebrand syndrome., Methods: VWF:RCo and VWF:Ag were evaluated with the VWF large multimer index as a reference, which represents the percentage of a patient's VWF high molecular weight multimer ratio to that of standard plasma in the VWF multimer analysis., Results: We analyzed 382 patients with AS having transaortic valve maximal pressure gradients of >30 mmHg, 27 patients with peripheral artery disease, and 46 control patients free of cardiovascular disease with osteoarthritis, diabetes, and so on. We assumed a large multimer index of <80% as loss of VWF large multimers since 59.0% of patients with severe AS had the indices of <80%, while no control patients or patients with peripheral artery disease, except for 2 patients, exhibited the indices of <80%. The VWF:RCo/VWF:Ag ratios, measured using an automated blood coagulation analyzer, were correlated with the indices (r
s = 0.470, P < .001). When the ratio of <0.7 was used as a cut-off point, the sensitivity and specificity to VWF large multimer indices of <80% were 0.437 and 0.826, respectively., Conclusion: VWF:RCo/VWF:Ag ratios of <0.7 may indicate loss of VWF large multimers with high specificity, but low sensitivity. VWF:RCo/VWF:Ag ratios in patients with AS having a ratio of <0.7 may be useful for monitoring the loss of VWF large multimers during their clinical courses., (© 2023 The Author(s).)- Published
- 2023
- Full Text
- View/download PDF
39. C2 Domains of Munc13-4 Are Crucial for Ca 2+ -Dependent Degranulation and Cytotoxicity in NK Cells.
- Author
-
Bin NR, Ma K, Tien CW, Wang S, Zhu D, Park S, Turlova E, Sugita K, Shirakawa R, van der Sluijs P, Horiuchi H, Sun HS, Monnier PP, Gaisano HY, and Sugita S
- Subjects
- Animals, Aspartic Acid genetics, Calcium Signaling, Cell Degranulation, Cells, Cultured, Cytotoxicity, Immunologic, Humans, Mice, Mice, Inbred C57BL, Mice, Mutant Strains, Mutation genetics, Protein Domains genetics, Rats, Killer Cells, Natural immunology, Lymphohistiocytosis, Hemophagocytic immunology, Mast Cells immunology, Membrane Proteins metabolism, Secretory Vesicles metabolism
- Abstract
In the immune system, degranulation/exocytosis from lymphocytes is crucial for life through facilitating eradication of infected and malignant cells. Dysfunction of the NK cell exocytosis process has been implicated with devastating immune diseases, such as familial hemophagocytic lymphohistiocytosis, yet the underlying molecular mechanisms of such processes have remained elusive. In particular, although the lytic granule exocytosis from NK cells is strictly Ca
2+ -dependent, the molecular identity of the Ca2+ sensor has yet to be identified. In this article, we show multiple lines of evidence in which point mutations in aspartic acid residues in both C2 domains of human Munc13-4, whose mutation underlies familial hemophagocytic lymphohistiocytosis type 3, diminished exocytosis with dramatically altered Ca2+ sensitivity in both mouse primary NK cells as well as rat mast cell lines. Furthermore, these mutations within the C2 domains severely impaired NK cell cytotoxicity against malignant cells. Total internal reflection fluorescence microscopy analysis revealed that the mutations strikingly altered Ca2+ dependence of fusion pore opening of each single granule and frequency of fusion events. Our results demonstrate that both C2 domains of Munc13-4 play critical roles in Ca2+ -dependent exocytosis and cytotoxicity by regulating single-granule membrane fusion dynamics in immune cells., (Copyright © 2018 by The American Association of Immunologists, Inc.)- Published
- 2018
- Full Text
- View/download PDF
40. Metformin directly binds the alarmin HMGB1 and inhibits its proinflammatory activity.
- Author
-
Horiuchi T, Sakata N, Narumi Y, Kimura T, Hayashi T, Nagano K, Liu K, Nishibori M, Tsukita S, Yamada T, Katagiri H, Shirakawa R, and Horiuchi H
- Subjects
- Animals, Antibodies, Neutralizing chemistry, Antibodies, Neutralizing pharmacology, Humans, Inflammation drug therapy, Inflammation metabolism, Metformin pharmacology, Mice, Protein Binding, Protein Domains, RAW 264.7 Cells, HMGB1 Protein antagonists & inhibitors, HMGB1 Protein metabolism, Metformin pharmacokinetics
- Abstract
Metformin is the first-line drug in the treatment of type 2 diabetes. In addition to its hypoglycemic effect, metformin has an anti-inflammatory function, but the precise mechanism promoting this activity remains unclear. High mobility group box 1 (HMGB1) is an alarmin that is released from necrotic cells and induces inflammatory responses by its cytokine-like activity and is, therefore, a target of anti-inflammatory therapies. Here we identified HMGB1 as a novel metformin-binding protein by affinity purification using a biotinylated metformin analogue. Metformin directly bound to the C-terminal acidic tail of HMGB1. Both in vitro and in vivo , metformin inhibited inflammatory responses induced by full-length HMGB1 but not by HMGB1 lacking the acidic tail. In an acetaminophen-induced acute liver injury model in which HMGB1 released from injured cells exacerbates the initial injury, metformin effectively reduced liver injury and had no additional inhibitory effects when the extracellular HMGB1 was blocked by anti-HMGB1-neutralizing antibody. In summary, we report for the first time that metformin suppresses inflammation by inhibiting the extracellular activity of HMGB1. Because HMGB1 plays a major role in inflammation, our results suggest possible new ways to manage HMGB1-induced inflammation., (© 2017 by The American Society for Biochemistry and Molecular Biology, Inc.)
- Published
- 2017
- Full Text
- View/download PDF
41. Platelets are highly activated in patients of chronic thromboembolic pulmonary hypertension.
- Author
-
Yaoita N, Shirakawa R, Fukumoto Y, Sugimura K, Miyata S, Miura Y, Nochioka K, Miura M, Tatebe S, Aoki T, Yamamoto S, Satoh K, Kimura T, Shimokawa H, and Horiuchi H
- Subjects
- Adult, Aged, Blood Platelets drug effects, Blood Platelets metabolism, Case-Control Studies, Chronic Disease, Female, Fibrin metabolism, Hemodynamics physiology, Humans, Hypertension, Pulmonary metabolism, Male, Middle Aged, P-Selectin metabolism, Platelet Glycoprotein GPIIb-IIIa Complex metabolism, Pulmonary Embolism metabolism, Regression Analysis, Thrombin pharmacology, ral GTP-Binding Proteins metabolism, rhoA GTP-Binding Protein metabolism, Blood Platelets pathology, Hypertension, Pulmonary pathology, Hypertension, Pulmonary physiopathology, Platelet Activation physiology, Pulmonary Embolism pathology, Pulmonary Embolism physiopathology
- Abstract
Objective: Chronic thromboembolic pulmonary hypertension (CTEPH) is a fatal disease that is distinct from pulmonary arterial hypertension (PAH). Although CTEPH is characterized by obstruction of major pulmonary artery because of chronic thrombus, it remains unclear whether CTEPH is associated with prothrombotic condition., Approach and Results: In addition to conventional markers, GTP-bound levels of Rap1, RhoA, RalA, Rac1, and Ras in platelets, which are implicated for platelet activation, were measured in patients without pulmonary hypertension (non-PH, n=15), patients with PAH (n=19), and patients with CTEPH (n=25). Furthermore, the responsiveness to ex vivo thrombin stimulation was also evaluated. The ratios of the P-selectin positive platelets in the non-PH patients, patients with PAH, and patients with CTEPH were 1.40% (median and interquartile range, 0.83-1.82), 2.40% (1.80-3.39), and 2.63% (1.90-8.22), respectively (non-PH versus CTEPH, P<0.01). The activated GPIIb/IIIa-positive platelets were 6.01% (1.34-7.87), 11.39% (5.69-20.86), and 9.74% (7.83-24.01), respectively (non-PH versus CTEPH, P=0.01). GTP-bound RhoA was 1.79% (0.94-2.83), 4.03% (2.01-5.14), and 2.01% (1.22-2.48), respectively (non-PH versus PAH, P=0.04), and GTP-bound RalA was 1.58% (1.08-2.11), 3.02% (2.03-3.54), and 2.64% (1.42-4.28), respectively (non-PH versus PAH, P=0.023; non-PH versus CTEPH, P=0.048). In contrast, Rac1, Rap1, or Ras was not activated in any groups. The platelets of patients with CTEPH exhibited hyperresponsiveness to ex vivo thrombin stimulation compared with those of non-PH patients when evaluated for the surface markers. Either D-dimer or fibrin degradation product level was not increased in patients with CTEPH., Conclusions: These results provide the first direct evidence that platelets of patients with CTEPH are highly activated and exhibit hyperresponsiveness to thrombin stimulation., (© 2014 American Heart Association, Inc.)
- Published
- 2014
- Full Text
- View/download PDF
42. Impact of platelet reactivity on long-term clinical outcomes and bleeding events in Japanese patients receiving antiplatelet therapy with aspirin.
- Author
-
Yamane K, Ikeda T, Taniguchi R, Watanabe S, Kawato M, Kondo H, Shirakawa R, Higashi T, Toma M, Tabuchi A, Tamura T, Takahashi K, Watanabe H, Yoshikawa Y, Kita T, Kimura T, and Horiuchi H
- Subjects
- Aged, Body Mass Index, Cardiovascular Diseases etiology, Cardiovascular Diseases prevention & control, Female, Follow-Up Studies, Hemorrhage chemically induced, Humans, Japan, Male, Middle Aged, Prognosis, Retrospective Studies, Risk Factors, Time Factors, Treatment Outcome, Aspirin therapeutic use, Blood Platelets drug effects, Blood Platelets metabolism, Hemorrhage prevention & control, Platelet Aggregation Inhibitors therapeutic use
- Abstract
Aim: Aspirin is an antiplatelet drug widely used for the prevention of cardiovascular disease; however, it is known to increase bleeding events. A low response to aspirin was reported to correlate with poor prognosis in patients undergoing antiplatelet therapy with aspirin. The aim of this study was to evaluate the impact of the antiplatelet activity of aspirin on cardiovascular and bleeding events in Japanese patients., Methods: We analyzed the clinical course of 239 Japanese patients undergoing antiplatelet therapy with aspirin for a median of 64 months in this study. Their residual platelet reactivity was examined at enrollment and after 2 years. The co-primary endpoints were the occurrence of major adverse cardiac and cerebrovascular events (MACCEs) and bleeding events., Results: The annual incidence of MACCEs and major bleeding events was 3.7% and 0.48%, respectively. With defined criteria, 67 patients (28%) were classified as low responders based on the platelet aggregability measured at enrollment. Low response to aspirin was not associated with increased MACCEs, while it clearly increased MACCEs in patients less than 70 years old (low responders 36.9% vs. responders 14.8%, log rank p=0.008). Five major types of bleeding occurred in the responders, but not in low responders, although the difference was not statistically significant (p= 0.07)., Conclusion: Low response to aspirin was not associated with the increase of long-term MACCEs, while it increased MACCEs in patients less than 70 years old; however, it tended to decrease major bleeding events in Japanese patients.
- Published
- 2012
- Full Text
- View/download PDF
43. Effects of PPIs and an H2 blocker on the antiplatelet function of clopidogrel in Japanese patients under dual antiplatelet therapy.
- Author
-
Yamane K, Kato Y, Tazaki J, Tada T, Makiyama T, Imai M, Jinnai T, Ikeda T, Shirakawa R, Kimura T, and Horiuchi H
- Subjects
- 2-Pyridinylmethylsulfinylbenzimidazoles therapeutic use, Aged, Asian People, Aspirin therapeutic use, Case-Control Studies, Clopidogrel, Cross-Over Studies, Drug Therapy, Combination, Enzyme Inhibitors therapeutic use, Female, Humans, Male, Omeprazole therapeutic use, Prognosis, Prospective Studies, Rabeprazole, Ticlopidine therapeutic use, Coronary Artery Disease drug therapy, Histamine H2 Antagonists therapeutic use, Platelet Aggregation drug effects, Platelet Aggregation Inhibitors therapeutic use, Proton Pump Inhibitors therapeutic use, Ticlopidine analogs & derivatives
- Abstract
Aim: Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel is essential after percutaneous coronary intervention (PCI). Clopidogrel is a prodrug and changed into active metabolite by cytochrome p450 enzymes (CYPs), especially CYP2C19. Proton pump inhibitors (PPIs) are used for the prevention of aspirin-induced gastrointestinal bleeding. PPIs are also metabolized by CYP2C19, although the degree of its contribution is dependent on the kind of PPI. Omeprazole, a PPI, has been reported to weaken the antiplatelet effects of clopidogrel. Famotidine, a histamine receptor type 2 (H2) blocker, could also be an alternative to PPIs. The aim of this study was to evaluate the effects of PPIs and an H2 blocker on the antiplatelet function of clopidogrel., Methods: Patients receiving DAPT due to prior PCI, who took either omeprazole or rabeprazole, were enrolled (n=25). The initial PPI was changed to the other PPI as a crossover study. In another study, patients undergoing DAPT without taking PPIs or H2 blockers were enrolled (n=30) and famotidine was added., Results: Platelet aggregability when taking omeprazole was higher than when taking rabeprazole, evaluated by an optical aggregometer using collagen as a stimulus (p=0.0051) and by the VerifyNow P2Y12 assay (p=0.0060). Platelet aggregability when taking rabeprazole was comparable to that in control patients (n=15). Concomitant use of famotidine had no effect., Conclusion: Omeprazole significantly reduced the antiplatelet effect of clopidogrel and this effect on clopidogrel was stronger than that of rabeprazole. Concomitant use of famotidine had no effect on the antiplatelet effect of clopidogrel.
- Published
- 2012
- Full Text
- View/download PDF
44. Direct binding of RalA to PKCη and its crucial role in morphological change during keratinocyte differentiation.
- Author
-
Shirai Y, Morioka S, Sakuma M, Yoshino K, Otsuji C, Sakai N, Kashiwagi K, Chida K, Shirakawa R, Horiuchi H, Nishigori C, Ueyama T, and Saito N
- Subjects
- Actins metabolism, Adenoviridae, Binding Sites, Calcium metabolism, Calcium pharmacology, Cell Shape drug effects, Cholesterol Esters pharmacology, Enzyme Activation, Epidermal Cells, Epidermis enzymology, Escherichia coli, Gene Expression physiology, Gene Silencing, HEK293 Cells, Humans, Mutation, Protein Binding physiology, Protein Kinase C genetics, Protein Structure, Tertiary, RNA, Small Interfering metabolism, Recombinant Proteins genetics, Transfection, ral GTP-Binding Proteins genetics, Cell Differentiation drug effects, Keratinocytes cytology, Keratinocytes enzymology, Protein Kinase C metabolism, Recombinant Proteins metabolism, ral GTP-Binding Proteins metabolism
- Abstract
During differentiation, keratinocytes undergo a dramatic shape change from small and round to large and flat, in addition to production of proteins necessary for the formation of epidermis. It has been shown that protein kinase C (PKC) η is crucial for keratinocyte differentiation. However, its role in this process has yet to be fully elucidated. Here, we show that catalytic activity is not necessary for enlarged and flattened morphology of human keratinocytes induced by overexpression of PKCη, although it is important for gene expression of the marker proteins. In addition, we identify the small G protein RalA as a binding partner of PKCη, which binds to the C1 domain, an indispensable region for the morphological change. The binding led activation of RalA and actin depolymerization associated with keratinocyte differentiation. siRNA techniques proved that RalA is involved in not only the keratinocyte differentiation induced by PKCη overexpression but also normal keratinocyte differentiation induced by calcium and cholesterol sulfate. These results provide a new insight into the molecular mechanism of cytoskeletal regulation leading to drastic change of cell shape.
- Published
- 2011
- Full Text
- View/download PDF
45. Characterization of the antiplatelet effect of aspirin at enrollment and after 2-year follow-up in a real clinical setting in Japan.
- Author
-
Ikeda T, Taniguchi R, Watanabe S, Kawato M, Kondo H, Shirakawa R, Yamane K, Toma M, Tamura T, Takahashi K, Watanabe H, Yoshikawa Y, Tabuchi A, Kita T, Kimura T, and Horiuchi H
- Subjects
- Aged, Aspirin pharmacokinetics, Blood Coagulation Tests, Calcium Channel Blockers pharmacology, Collagen pharmacology, Female, Follow-Up Studies, Humans, Japan, Male, Middle Aged, Platelet Aggregation Inhibitors pharmacokinetics, Platelet Function Tests, Sex Factors, Time Factors, Aspirin pharmacology, Drug Resistance drug effects, Platelet Aggregation Inhibitors pharmacology
- Abstract
Background: Aspirin is an antiplatelet drug widely used for the prevention of cardiovascular diseases. It has been reported that some patients who exhibit a reduced antiplatelet effect of aspirin have higher cardiovascular risk. It is still controversial whether the antiplatelet effect of aspirin diminishes after a few years of treatment. This study aimed to evaluate the antiplatelet effect of aspirin and its 2-year change in Japanese patients., Methods and Results: Collagen-induced platelet-aggregability was measured at enrollment by conventional optical aggregometer in 239 patients undergoing antiplatelet therapy with aspirin alone. Among them, 167 patients were evaluated after 2 years. Whole blood aggregability based on the screen-filtration method was also evaluated. Optical aggregometer studies showed that 27% of patients were low-responders. Multivariate analyses revealed that female sex and non-use of calcium-channel blockers were associated with low responsiveness. The antiplatelet effect of aspirin did not decrease after 2 years. Similar data were obtained with the whole blood aggregometer., Conclusions: In this Japanese patient group, 27% were low-responders to aspirin, and the antiplatelet effect of aspirin did not decrease after a 2-year interval.
- Published
- 2010
- Full Text
- View/download PDF
46. Evaluation of the antiplatelet effects of cilostazol, a phosphodiesterase 3 inhibitor, by VASP phosphorylation and platelet aggregation.
- Author
-
Yamamoto H, Takahashi K, Watanabe H, Yoshikawa Y, Shirakawa R, Higashi T, Kawato M, Ikeda T, Tabuchi A, Morimoto T, Kita T, and Horiuchi H
- Subjects
- Adult, Alprostadil pharmacology, Cilostazol, Humans, Male, Middle Aged, Phosphorylation drug effects, Blood Platelets metabolism, Cell Adhesion Molecules metabolism, Microfilament Proteins metabolism, Phosphodiesterase 3 Inhibitors, Phosphoproteins metabolism, Platelet Aggregation drug effects, Platelet Aggregation Inhibitors administration & dosage, Tetrazoles administration & dosage
- Abstract
Background: Cilostazol, a phosphodiesterase 3 inhibitor, is an antiplatelet drug that is widely used for preventing cardiovascular events, although, to date, there are few methods for evaluating its effects., Methods and Results: Blood samples were taken at baseline and at 3 and 12 h in 10 healthy male subjects after 100 mg cilostazol intake. Each sample was examined by Western blot for phosphorylation levels of vasodilator-stimulated phosphoprotein (VASP), an abundant cAMP-dependent kinase substrate in platelets, and by the optical aggregometer for ADP- and collagen-induced aggregation, before and after 8 nmol/L prostaglandin E(1) (PGE(1)) treatment. Cilostazol intake did not affect VASP phosphorylation levels or the maximal aggregation rates without PGE(1) treatment. However, cilostazol intake apparently enhanced PGE(1)-induced VASP phosphorylation and PGE(1)-mediated reduction of ADP-and collagen-induced maximal aggregation rates. Levels of VASP phosphorylated at Ser157 were correlated and the maximal aggregation rates induced by ADP were inversely correlated with cilostazol concentrations in the plasma., Conclusion: The antiplatelet effects of cilostazol intake could be evaluated by measuring VASP phosphorylation levels and maximal aggregation rates in platelets by ex vivo treatment with a low concentration of PGE(1).
- Published
- 2008
- Full Text
- View/download PDF
47. Purification and functional analysis of a Rab27 effector munc 13-4 using a semi-intact platelet dense-granule secretion assay.
- Author
-
Shirakawa R, Higashi T, Kondo H, Yoshioka A, Kita T, and Horiuchi H
- Subjects
- Blood Platelets metabolism, Chromatography, Affinity, Electrophoresis, Polyacrylamide Gel, Humans, Recombinant Proteins metabolism, Serotonin metabolism, rab27 GTP-Binding Proteins, Blood Platelets physiology, Membrane Proteins isolation & purification, Membrane Proteins physiology, rab GTP-Binding Proteins physiology
- Abstract
We have demonstrated that small GTPase Rab27 regulates dense-granule secretion in platelets. Using Rab27a affinity chromatography, we purified Munc 13-4 as a novel Rab27a interacting protein from platelet cytosol. This chapter describes the purification of Munc 13-4 and an in vitro assay system analyzing the mechanism of dense-granule secretion in platelets. The activity of Munc 13-4 is tested in this assay.
- Published
- 2005
- Full Text
- View/download PDF
48. Direct demonstration of involvement of the adaptor protein ShcA in the regulation of Ca2+-induced platelet aggregation.
- Author
-
Higashi T, Yoshioka A, Shirakawa R, Tabuchi A, Nishioka H, Kita T, and Horiuchi H
- Subjects
- Adaptor Proteins, Vesicular Transport genetics, Adaptor Proteins, Vesicular Transport immunology, Animals, Antibodies immunology, Cytosol metabolism, Integrin beta3 metabolism, Mice, Protein Isoforms genetics, Shc Signaling Adaptor Proteins, Src Homology 2 Domain-Containing, Transforming Protein 1, Adaptor Proteins, Signal Transducing, Adaptor Proteins, Vesicular Transport metabolism, Blood Platelets physiology, Calcium metabolism, Platelet Aggregation physiology
- Abstract
Platelet aggregation is mediated by conformational change of integrin alpha(IIb)beta(3). Tyrosine-phosphorylation of cytoplasmic domain of beta(3) upon platelet activation has been demonstrated to play a critical role in this process. Recently, the adaptor protein ShcA has been shown to bind to the tyrosine-phosphorylated beta(3), while it remains open whether ShcA plays any role in platelet aggregation. Here, we show that ShcA bound to tyrosine-phosphorylated beta(3)-tail peptide through its phosphotyrosine-binding domain in vitro. Then, we examined the involvement of ShcA in platelet aggregation by a previously established in vitro assay using platelets permeabilized with streptolysin-O, where exogenous addition of platelet cytosol is required for reconstitution of the Ca(2+)-induced aggregation. When ShcA was specifically depleted with anti-ShcA antibody from the cytosol, this ShcA-depleted cytosol lost the aggregation-supporting activity, which was rescued by addition of purified recombinant ShcA. Thus, ShcA is essential for the Ca(2+)-induced platelet aggregation.
- Published
- 2004
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.